INMB (INmune Bio Inc) Sof foyda

INMB (INmune Bio) - kompaniyaning tovar belgisi

INmune Bio, Inc. (INMB) demensiyaga qarshi kurashish uchun selektiv TNF ingibitorlarini ishlab chiqmoqda. Kompaniyaning joriy daromad darajalari yashirin marja risklarini aniqlashga yordam beradi, bunda oxirgi ko'rsatkich -0.02 ni tashkil etadi. Moliyaviy asos yallig'lanish patologiyalarining immunoterapiyasi uchun davlat moliyalashtirishiga tayanadi. Saraton va Altsgeymer terapiyasi uchun DN-TNF pipeline'ining ishlab chiqilishi tizimli immun suppressiyalarsiz faol biznes o'sishini ta'minlaydi.

INMB (INmune Bio, Inc.) Sof foyda tarixi 04.07.2022dan 29.10.2026gacha

INmune Bio (INMB) kompaniyasining tahliliy kesimlari va maʼlumotlar hisoboti

- narx va narxlar bo'yicha konsensus prognoz:
Aksiya kotirovkalari INmune Bio Corporation|INMB - Tahlilchilar konsensus prognozi
- biznesning bozor baholash ko'rsatkichlari:
Bozor kapitallashuvi INmune Bio Corporation|INMB - Kompaniyani butunlay sotib olishdagi haqiqiy narx
- balans kapitallashuvi bo'yicha ma'lumotlar:
Aksiyaning buxgalteriya qiymati INmune Bio|INMB - Balans kapitallashuvi|Balans qiymatiga nisbatan bozor kapitallashuvi inmunebio.com|INMB - Kompaniyaning jami aktivlari
- qarzlar va to'lov qobiliyati haqida ma'lumot:
Umumiy qarzning xususiy kapitalga nisbati INmune Bio, Inc.|INMB - Uzoq muddatli qarzning o'z kapitaliga nisbati|Qisqa muddatli qarzning o'z kapitaliga nisbati INmune Bio Inc|INMB - Kompaniyaning umumiy qarzi|Balans kapitallashuviga qarzlar INmune Bio Corporation|INMB - Kompaniyaning uzoq muddatli qarzi|Kompaniyaning qisqa muddatli qarzdorligi INmune Bio|Shoshilinch likvidlik inmunebio.com
- sof daromad va qiymat multiplikatorlari ko'rsatkichlari:
INMB - Sof foyda
Kompaniyaning jamlanma tahlili:INmune Bio, Inc.
INmune Bio Corp asosiy tovari

INmune Bio, Inc. (INMB) kompaniyasining Altsgeymer terapiyasi va onkologiya uchun selektiv TNF ingibitorlarini ishlab chiqishga kiritayotgan investitsiyalari uning joriy o'sish bosqichidagi yuqori kapital intensivligini keltirib chiqarmoqda. Kompaniyaning daromad va xarajatlar balansini tahlil qilish orqali investor real biznes qiymatini bozor shovqinlaridan ajratuvchi sof moliyaviy natijani aniqlashi mumkin, bu esa klinik sinovlar davomida operatsion modelning barqarorligi va to'plangan kapital dinamikasini kuzatish imkonini beradi.

Asosiy raqobatchilar

Sof daromad argenx BVBA|BNTX (BioNTech SE) - Sof foyda|Sof foyda Abivax Pharma|Sof daromad ADMA (ADMA Biologics, Inc.)|PTGX (Protagonist Therapeutics, Inc.) - Yakuniy foyda|Sof foyda IMVT (Immunovant Corp)|Sof moliyaviy natija Kiniksa Corp (KNSA)|GRFS - Kompaniyaning sof foydasi|adaptivebiotech.com (ADPT) - Sof daromad|Celldex Therapeutics, Inc. (CLDX) - Kompaniyaning sof foydasi|Sof daromad Aurinia Pharmaceuticals Inc|Sof daromad BCRX|Sof foyda Vera Corp|Kompaniyaning sof foydasi Dianthus Therapeutics (DNTH)|pharvaris.com - Kompaniya foydasi|Sof foyda ABCL (AbCellera Biologics Inc)|Tourmaline Bio Inc (TRML) - Kompaniyaning sof daromadi|Intrexon - Sof foyda|Sof moliyaviy natija Pharming Corp PHAR|Nektar Therapeutics (NKTR) - Kompaniyaning sof foydasi|Kompaniya foydasi UPB|Kompaniyaning sof foydasi Zenas Biopharma|Sof daromad Immunome Inc (IMNM)|Sof daromad GOSS (Gossamer Corp)|Sof foyda KalVista Corp (KALV)|Kompaniyaning sof foydasi Septerna Inc SEPN|PVLA: Kompaniya foydasi|Savara - Sof foyda|Kompaniyaning sof daromadi Rigel Pharma|ANAB (AnaptysBio Corp) - Sof daromad|Astria Corp - Yakuniy foyda|ENGN (enGene Holdings Inc.) - Sof foyda|Kompaniyaning sof foydasi RAPT|Sof foyda JBIO|Sof moliyaviy natija Aclaris Therapeutics Inc.|Kompaniyaning sof foydasi Kyverna KYTX|Tiziana Life Sciences, Ltd. (TLSA) - Kompaniyaning sof daromadi|CABA: Sof daromad|Yakuniy foyda VTYX (ventyxbio.com)|THTX: Sof foyda|AVTX - Sof moliyaviy natija|Kompaniyaning sof foydasi Eledon|Kompaniya foydasi AGEN (Agenus, Inc)|Sof foyda CLYM|Sof daromad zurabio.com ZURA|aTyr Pharma - Sof daromad|Sof moliyaviy natija Adagene Inc (ADAG)|Ikena Oncology, Inc. - Sof foyda|Sof moliyaviy natija Shattuck Labs, Inc. STTK|equilliumbio.com (EQ) - Kompaniyaning sof foydasi|Kompaniya foydasi CNTB|Kompaniyaning sof foydasi Immunic Therapeutics|Sof daromad Atara Biotherapeutics Inc (ATRA)|Sof foyda IFRX|Kompaniyaning sof foydasi XFOR (X4 Pharmaceuticals, Inc)|Kompaniyaning sof foydasi Adicet Bio, Inc. ACET|CELU (Celularity Inc) - Soliqdan keyingi foyda|Barinthus Biotherapeutics plc - Sof foyda|Yakuniy foyda KZR (Kezar Life Sciences Inc.)|SABS: Sof foyda|Akari Therapeutics, Plc (AKTX) - Sof foyda|Kompaniyaning sof foydasi Enlivex Therapeutics Ltd|QTTB: Yakuniy foyda|Kompaniyaning sof foydasi GeoVax (GOVX)|Sof daromad Edesa Biotech Inc EDSA|Sof foyda IBIO (iBio Corp)|Sof foyda Carisma Therapeutics Inc CARM|XTLB: Sof daromad|Yakuniy foyda BOLT (Bolt Biotherapeutics)|HCWB: Sof foyda|APVO - Sof moliyaviy natija|Kompaniyaning sof foydasi AIM ImmunoTech|Sof daromad Aditxt Corp (ADTX)|Kompaniyaning sof foydasi GRI Bio, Inc. (GRI)|Sof daromad xortx.com XRTX|Vyome Holdings - Sof daromad|Sof foyda Revelation Biosciences Inc REVB|INDP - Kompaniyaning sof foydasi|SCNI (BiondVax Pharmaceuticals) - Kompaniya foydasi|CALI: Sof foyda|Kompaniyaning sof daromadi Affimed N.V. (AFMD)|ALLK (Allakos Inc) - Sof foyda|HOOKIPA (HOOK) - Sof moliyaviy natija|Kompaniyaning sof foydasi IGM Biosciences, Inc. (IGMS)|iTeos Pharma - Kompaniya foydasi|Kompaniyaning sof foydasi Ocean Biomedical, Inc. OCEA|TCBP - Sof daromad|THRD: Sof daromad